Study Design and Patients
ICH, bleeding, hematoma
BLEEDING, HEMATOMA
Patients were enrolled if they met the following criteria: (1) primary ICH with symptom onset within 48 h, (2) age between 18 and 80 years, (3) bleeding into deep grey matter (basal ganglionic and thalamus) and the amount of bleeding between 5 and 30 mL, and (4) the ability to provide written informed consent. This study was conducted according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Beijing Tiantan Hospital (approval number: YW2016-011–04). Our study was an analysis of patients enrolled in the deproteinized calf blood extract in an acute ICH trial (NCT03260153). Details of this trial are described in the Supplementary Material and Supplementary Table 1. In brief, the research was a randomized, double-blind, placebo-controlled clinical trial to investigate whether the deproteinized calf blood extract could improve functional outcomes in patients with ICH. The results showed that there were no significant effects of deproteinized calf blood extract on hematoma volume, PHE volume, PHE expansion rate, presence of CE, or clinical outcomes in patients with ICH. This indicates that the intervention of the original research was not expected to have an impact on the conclusion in the present study.